428 results about "Tetrahydropyran" patented technology

There are provided a liquid crystalline compound having a large negative Deltaepsilon, low viscosity, a large K33 / K11 value, a small Deltaepsilon / epsilonL and mutually excellent solubility even at extremely low temperature; a liquid crystal composition prepared from a liquid crystalline compound; and a liquid crystal display device fabricated from such a liquid crystal composition. The liquid crystalline compound of the present invention is a liquid crystalline compound represented by the following general formula (1): where, R<1 >represents hydrogen, fluorine, an alkyl group having 1 to 15 carbon atoms, or an alkenyl group having 2 to 15 carbon atoms; each of rings A<1>, A<2>, and A<3 >independently represents trans-1,4-cyclohexylene group, 1,4-cyclohexenylene group, trans-1,4-silacyclohexylene group, 1,4-phenylenegroup, 2,3-difluoro-1,4-phenylene group, 2-fluoro-1,4-phenylene group, 3-fluoro-1,4-phenylene group, pyrimidine-2,5-diyl group, pyridine-2,5-diyl group, 1,3-dioxane-2,5-diyl group, tetrahydropyrane-2,5-diyl group, 1,3-dithiane-2,5-diyl group, or tetrahydrothiopyrane-2,5-diyl group; X<1 >represents hydrogen or fluorine; Y<1 >represents hydrogen or an alkyl group having 1 to 15 carbon atoms; 1 represents an integer from 1 to 10; and each of m and n independently represents 0 or 1.

The present invention is related to compounds comprising six-membered rings capable of being incorporated into nucleic acids. Particularly, the six-membered ring is a derivative of cyclohexane, cyclohexene, tetrahydropyran, tetrahydrothiopyran or piperidine. These compounds may be used to build up oligomeric compounds. The invention is further related to uses of these oligomeric compounds for hybridization and as probes. In addition, methods for the detection of nucleic acids are provided wherein the oligomeric compounds are used.

Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.

This invention provides aryl-substituted acyclic enediyne compounds of formula (I):or a pharmaceutically acceptable salt or solvate thereof,whereinR1=R2=H; or R1 and R2 together form a moiety represented by the formulaR3 represents a substituted or unsubstituted alkyl having 4-30 carbon atoms, or a substituted or unsubstituted aryl group having 3-30 carbon atoms; andR4 represents a substituted or unsubstituted aryl group having 3-30 carbon atoms;with the proviso that R3 is not butyl, pentyl, tetrahydropyranyloxymethyl, tetrahydropyranyloxypropyl or phenyl when R1=R2=H and R4 is o-cyanophenyl,; and with the proviso that R3 is not butyl when R1=R2=H and R4 is phenyl.The compounds of formula (I) are found to have inhibitory activities against topoisomerase I or act as a S phase or G2 / M phase blocker.

The invention is to provide a liquid crystal composition that satisfies at least one characteristic among the characteristics such as a high maximum temperature of a nematic phase, a low minimum temperature of a nematic phase, a small viscosity, a large optical anisotropy, a negatively large dielectric anisotropy, a large specific resistance, a high stability to ultraviolet light, a high stability to heat and so forth. A liquid crystal composition having a negative dielectric anisotropy comprising two components, wherein the first component is at least one compound selected from the group of compounds represented by formula (1-1) and formula (1-2), and the second component is at least one compound selected from the group of compounds represented by formula (2-1) and formula (2-2):wherein R1 and R2 are each independently alkyl having 1 to 12 carbons, alkoxy having from 1 to 12 carbons, alkenyl having 2 to 12 carbons or alkenyl having 2 to 12 carbons, arbitrary hydrogen of which is replaced by fluorine; Z1 is a single bond, ethylene, methyleneoxy or carbonyloxy; ring A and ring B are each independently tetrahydropyran-2,5-diyl, 1,4-cyclohexylene, or 1,4-phenylene, at least one of ring A and ring B is tetrahydropyran-2,5-diyl.

An electrolyte solution containing a solvent mainly composed of a BF3-cyclic ether complex and a supporting electrolyte. Preferably, the cyclic ether is composed of one or more substances selected from optionally substituted tetrahydrofurans and optionally substituted tetrahydropyrans.

A liquid crystal compound selected from a group of compounds represented by formula (a):wherein Ra and Rb are each independently alkyl having 1 to 10 carbons, alkoxy having 1 to 9 carbons, alkoxyalkyl having 2 to 9 carbons, alkenyl having 2 to 10 carbons, alkenyloxy having 2 to 9 carbons, fluoroalkyl having 1 to 10 carbons or fluoroalkoxy having 1 to 9 carbons; ring A1, ring A2 and ring A3 are each independently trans-1,4-cyclohexylene, trans-1,3-dioxane-2,5-diyl, trans-tetrahydropyran-2,5-diyl, 1,4-phenylene, 2-fluoro-1,4-phenylene, 2,3-difluoro-1,4-phenylene, 2,5-difluoro-1,4-phenylene, 2,6-difluoro-1,4-phenylene, pyridine-2,5-diyl, 6-fluoropyridine-2,5-diyl or pyridazine-2,5-diyl; Z1, Z2 and Z3 are each independently a single bond, —(CH2)2—, —CH═CH—, —C≡C—, —CH2O, —OCH2—, —COO—, —OCO—, —OCF2—, —CF2O—, —CH2CH2OCF2— or —CF2OCH2CH2—; l, m and n are each independently 0, 1 or 2, provided that l+m+n is 0, 1, 2 or 3; one of X1 and X2 is fluorine, and the other is chlorine; Q isand atoms comprising the compound each may be an isotope thereof.

Novel, enantiopure, substituted 4-deoxypentenosides (4-DPs) and related dihydropyrans (DHPS) are prepared from common carbohydrates via a novel process. The 4-DPs and related DHPs are amenable to a broad range of stereoselective transformations and are used as synthetic intermediates to prepare a variety of enantiopure tetrahydropyrans (THPs), including rare or exotic sugars and other complex THPs of commercial or medicinal value. In one embodiment of the instant invention, 4-DPs are converted to L-sugars in a novel process that offers distinct advantages over known synthetic methods.